RU2008133932A - CELLULAR Adenocarcinoma CELL LINE SKOV-KAT - Google Patents

CELLULAR Adenocarcinoma CELL LINE SKOV-KAT Download PDF

Info

Publication number
RU2008133932A
RU2008133932A RU2008133932/13A RU2008133932A RU2008133932A RU 2008133932 A RU2008133932 A RU 2008133932A RU 2008133932/13 A RU2008133932/13 A RU 2008133932/13A RU 2008133932 A RU2008133932 A RU 2008133932A RU 2008133932 A RU2008133932 A RU 2008133932A
Authority
RU
Russia
Prior art keywords
kat
cell line
adenocarcinoma cell
cellular
line skov
Prior art date
Application number
RU2008133932/13A
Other languages
Russian (ru)
Other versions
RU2404244C2 (en
Inventor
Дмитрий Владимирович Карпенко (RU)
Дмитрий Владимирович Карпенко
Олег Анатольевич Стремовский (RU)
Олег Анатольевич Стремовский
Сергей Михайлович Деев (RU)
Сергей Михайлович Деев
Original Assignee
Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН (RU)
Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН (RU), Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН filed Critical Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН (RU)
Priority to RU2008133932/10A priority Critical patent/RU2404244C2/en
Publication of RU2008133932A publication Critical patent/RU2008133932A/en
Application granted granted Critical
Publication of RU2404244C2 publication Critical patent/RU2404244C2/en

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Клеточная линия аденокарциномы яичника человека SKOV-kat, гиперэкспрессирующая онкомаркер HER2/neu и флуоресцирующая в дальней красной области спектра 600-700 нм, для использования в скрининге противоопухолевых препаратов in vivo.The human ovarian adenocarcinoma cell line SKOV-kat, which overexpresses the HER2 / neu tumor marker and fluoresces in the far red spectral region 600-700 nm, for use in in vivo screening of anticancer drugs.

Claims (1)

Клеточная линия аденокарциномы яичника человека SKOV-kat, гиперэкспрессирующая онкомаркер HER2/neu и флуоресцирующая в дальней красной области спектра 600-700 нм, для использования в скрининге противоопухолевых препаратов in vivo. The human ovarian adenocarcinoma cell line SKOV-kat, which overexpresses the HER2 / neu tumor marker and fluoresces in the far red spectral region 600-700 nm, for use in in vivo screening of anticancer drugs.
RU2008133932/10A 2008-08-20 2008-08-20 STABLE CELL LINE OF HUMAN OVARIAN ADENOCARCINOMA SKOV-kat RU2404244C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2008133932/10A RU2404244C2 (en) 2008-08-20 2008-08-20 STABLE CELL LINE OF HUMAN OVARIAN ADENOCARCINOMA SKOV-kat

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2008133932/10A RU2404244C2 (en) 2008-08-20 2008-08-20 STABLE CELL LINE OF HUMAN OVARIAN ADENOCARCINOMA SKOV-kat

Publications (2)

Publication Number Publication Date
RU2008133932A true RU2008133932A (en) 2010-02-27
RU2404244C2 RU2404244C2 (en) 2010-11-20

Family

ID=42127494

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008133932/10A RU2404244C2 (en) 2008-08-20 2008-08-20 STABLE CELL LINE OF HUMAN OVARIAN ADENOCARCINOMA SKOV-kat

Country Status (1)

Country Link
RU (1) RU2404244C2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110244502A1 (en) 2007-08-10 2011-10-06 Whitehead Institute For Biomedical Research Hormone responsive tissue culture system and uses thereof
BR112013029444A2 (en) * 2011-03-24 2017-01-17 Brigham & Womens Hospital compositions and methods for culturing cells from normal human tube-ovarian epithelium and human tube-ovarian tumors
RU2709675C1 (en) * 2018-11-15 2019-12-19 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Нижегородский государственный университет им. Н.И. Лобачевского" Stable human breast cancer carcinoma cell line skbr-kat

Also Published As

Publication number Publication date
RU2404244C2 (en) 2010-11-20

Similar Documents

Publication Publication Date Title
CY1119324T1 (en) ANTIBODIES AGAINST CSF-1R
CY1119591T1 (en) SPECIAL CONNECTION PROTEINS AND THEIR USES
CY1119129T1 (en) ANHYDRATE CRYSTAL FORM OF DIETHOXY DOXACEL AND ITS PRODUCTION PROCEDURES
CY1122161T1 (en) ANTI-CD38 CONJUGATED ANTIBODIES
MD3515487T2 (en) Bi specific anti-MUC16-cd3 antibodies and anti-MUC16 drug conjugates
MX2017003246A (en) Macropinocytosing human anti-cd46 antibodies and targeted cancer therapeutics.
CY1118608T1 (en) ANTIBODIES FOR CLAUDINE-expressing CANCER 6
ES2534430T3 (en) Modulation method of epidermal growth factor receptor (EGFR) expression that involves miRNA
CL2016002359A1 (en) Antibodies that bind to human epidermal growth receptor (anti-egfr) and anti-egfr antibody and drug conjugates
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
MX2019011494A (en) Duocarmycin adcs showing improved in vivo antitumor activity.
WO2014018563A3 (en) Methods for the treatment of cancer
PH12014502507A1 (en) Anti-angiogenesis therapy for the treatment of breast cancer
WO2007013950A3 (en) Combination therapy of her expressing tumors
MX2013002084A (en) Biomarkers and methods of treatment.
NI201200175A (en) BLADDER CANCER TREATMENT METHODS
CY1114050T1 (en) CLAUDIN-18 Monoclonal Antibodies In Cancer Treatment
CL2012000949A1 (en) Compounds derived from 3 - [(4-phenylpiperidin-1-yl) carbonill] piperidine inhibitors of the protein hdm2; pharmaceutical composition comprising one of the compounds; and its use of the compounds in the preparation of a useful medicine for the treatment of different types of cancer, such as bladder, colon, kidney and others.
WO2011057099A3 (en) Treating basal-like genotype cancers
MX2009009926A (en) Monoclonal human tumor-specific antibody.
WO2005094348A3 (en) Anti-lfl2 antibodies for the diagnosis, prognosis and treatment of cancer
EA201101651A1 (en) CONTINUOUS INTRODUCTION OF INTEGRINE LIGANDS FOR CANCER TREATMENT
WO2009004484A3 (en) Trim24 (tifla) as p53 modulator and cancer target
EP3736022A3 (en) Treatment and diagnosis of colon cancer
MX2013002155A (en) Compounds for treatment of cancer.

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20170821

NF4A Reinstatement of patent

Effective date: 20180718